Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico maintains a Neutral rating on Vera Therapeutics (NASDAQ:VERA) and raises the price target from $12 to $16.
August 11, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush maintains a Neutral rating on Vera Therapeutics and raises the price target from $12 to $16. This could potentially lead to a positive market reaction.
The raised price target by Wedbush indicates a positive outlook for Vera Therapeutics. This could potentially lead to a positive market reaction, increasing the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100